Compare AdaptHealth Corp (AHCO) vs Credo Technology Group Holding Ltd (CRDO) Price & Performance

AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.

The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.

CRDO trades at $265.55, up 9.77% in 24 hours, with strong bullish momentum from moving averages and recent earnings beats. The stock shows robust fundamentals with 35.37% net income margin and 34.41% ROE, though valuations are elevated at P/E 105.8 and P/S 37.44. Recent news highlights AI-driven growth in connectivity solutions, with revenue surging 157% YoY in Q4 2026.

Outlook remains positive given analyst consensus of $273.33 price target and 86.7% buy ratings, but high valuations and competitive pressures pose risks. Continued execution on AI networking demand could drive further upside, while any slowdown in growth may trigger multiple compression.